Refine by
Pharma 2018 Technology Articles & Analysis: Older
43 news found
In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. Specializing in complex biologic formulations, Biologics & Biosimilars service team of CD Formulation is revolutionizing how drug conjugate products are conceptualized and produced, ...
Shanghai, China – June 14, 2024 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in the production of PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services for Active Pharmaceutical Ingredients (APIs) and intermediates, is excited to announce its participation in CPHI China 2024. The event will take place from June 19 to 21, 2024, at the Shanghai New ...
[Cambridge, June 8, 2024] Protheragen-ING is pleased to announce its participation in the 26th SAPA-NE Annual Conference. The event will be held at the Cambridge Marriott Boston (50 Broadway, Cambridge, MA 02142), on June 8, 2024, 9 am - 5 pm EDT. About SAPA-NE SAPA (Sino-American Pharmaceutical Professionals Association) is one of the most active and largest Chinese-based biopharmaceutical ...
[Philadelphia, May 7-9, 2024] - Protheragen-ING, a pharmaceutical products supplier focused on innovative drug discovery and development, is pleased to announce its participation in the highly anticipated 2024 CPHI North America Conference. The event is scheduled to take place from May 7 to May 9, 2024, at the Pennsylvania Convention Center in East Philadelphia, Pennsylvania. Our booth number is ...
In the pursuit of optimizing tablet performance, CD Formulation, a leading provider of pharmaceutical analysis services, has unveiled a groundbreaking powder flowability testing method. This cutting-edge technology promises to revolutionize tablet manufacturing by ensuring high-quality and consistent tablet production for pharmaceutical companies worldwide. Powder flowability plays a crucial ...
In recent years, the field of drug delivery has experienced significant advancements in the development of innovative delivery systems such as microspheres and microneedles. These advanced systems offer unique benefits, including enhanced drug stability, sustained release, and targeted delivery. However, the successful formulation and optimization of these delivery systems pose significant ...
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
As a reliable service provider in pharmaceutical formulation development, CD Formulation constantly expands its service range and today announces to offer a comprehensive portfolio of services for drug delivery system (DDS) research, including microneedle technology services, oral thin films technology services, microencapsulation technology services, liposome drug delivery technology services, ...
EsoCap has announced that scientists from the University of Greifswald have published important data regarding a hot-melt extrusion-based spinning process to produce pharmaceutical fibers and yarns. This spinning process is very useful in the context of EsoCap’s novel drug delivery technology, enabling targeted and long-lasting local therapy of the esophagus. The rapidly dissolving yarn is ...
Kurve Therapeutics has succeeded in bypassing the blood-brain barrier with their patented Controlled Particle Dispersion® (CPD) technology, creating new hope in the treatment of central nervous system disorders. The company urges CNS researchers to reach out for collaboration in providing care for this very large global population. Led by a team of experienced entrepreneurs with ...
The Korea Health Industry Development Institute (KHIDI) announced on the 31st that it held the 'China Pharmaceutical Bio Investment Briefing (IR)' on the 20th, where domestic pharmaceutical companies introduced their technologies to Chinese investors. This event was jointly held with the Shanghai office of NH Investment & Securities. 10 domestic companies made IR presentations. KISA is ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life ...
Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag. Use of a highly innovative proprietary liposome encapsulated technology leads to a better CBD absorption. This New True North Nectar product line in liquid and powder formats are expected to launch in select markets in Q4 ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has commenced a Phase 2 clinical program for its third-generationiLink™ therapy designed to treat keratoconus. ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. The transaction pulled in ...
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D. as General Counsel and Corporate Secretary. Lori Kunkel, M.D. and Ron Dror, Ph.D. have also joined ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED). ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia. GLK-302 is the second investigational ...
Approximately 70% of Subjects were Well-Controlled on iDose TR with the Same or Fewer Topical IOP-Lowering Medications at 36 Months vs. Screening Favorable Safety Profile Through 36 Months . SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, ...